<?xml version='1.0' encoding='utf-8'?>
<document id="20705951"><sentence text="Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers."><entity charOffset="22-31" id="DDI-PubMed.20705951.s1.e0" text="lopinavir" /><entity charOffset="36-45" id="DDI-PubMed.20705951.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20705951.s1.e0" e2="DDI-PubMed.20705951.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20705951.s1.e0" e2="DDI-PubMed.20705951.s1.e1" /></sentence><sentence text="The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355"><entity charOffset="87-96" id="DDI-PubMed.20705951.s2.e0" text="lopinavir" /><entity charOffset="97-106" id="DDI-PubMed.20705951.s2.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20705951.s2.e0" e2="DDI-PubMed.20705951.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20705951.s2.e0" e2="DDI-PubMed.20705951.s2.e1" /></sentence><sentence text=" In group A, 26 healthy participants were administered LPV/r (400mg/100mg) twice daily for 14 days, followed by coadministration of BILR 355, 150 mg twice daily for an additional 7 days" /><sentence text=" Pharmacokinetic assessments were performed on days 14 and 21" /><sentence text=" In group B, 8 healthy participants were given BILR 355/ritonavir (BILR 355/r, 150 mg/100mg) twice daily for 7 days"><entity charOffset="56-65" id="DDI-PubMed.20705951.s5.e0" text="ritonavir" /></sentence><sentence text=" The pharmacokinetic data from group B (BILR 355/r-alone group) were also pooled with group B subjects from 3 similar phase I drug-drug interaction trials performed in parallel to this study" /><sentence text=" Coadministration with LPV/r resulted in a 51% decrease in steady-state area under plasma concentration-time curve from 0 to 12 hours (AUC(0-12,ss)) and steady-state maximum measured plasma concentration over a dosing interval (C(max,ss)) and a 50% decrease in steady-state plasma concentration 12 hours post last dosing (C(12,ss)) for BILR 355" /><sentence text=" Exposure to LPV was not changed after coadministration" /><sentence text=" BILR 355/r was well tolerated in this study" /><sentence text=" There was no evidence of increased risk of lopinavir or ritonavir toxicity upon coadministration with BILR 355"><entity charOffset="44-53" id="DDI-PubMed.20705951.s10.e0" text="lopinavir" /><entity charOffset="57-66" id="DDI-PubMed.20705951.s10.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20705951.s10.e0" e2="DDI-PubMed.20705951.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20705951.s10.e0" e2="DDI-PubMed.20705951.s10.e1" /></sentence><sentence text="" /></document>